- Research article
- Open Access
- Open Peer Review
Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer
- Sandra Waalkes†1,
- Faranaz Atschekzei†1,
- Mario W Kramer1,
- Jörg Hennenlotter2,
- Gesa Vetter1,
- Jan U Becker1,
- Arnulf Stenzl2,
- Axel S Merseburger1Email author,
- Andres J Schrader3,
- Markus A Kuczyk1 and
- Jürgen Serth1
© Waalkes et al; licensee BioMed Central Ltd. 2010
- Received: 17 May 2010
- Accepted: 22 September 2010
- Published: 22 September 2010
Fibronectin 1 (FN1) is a glycoprotein involved in cellular adhesion and migration processes. The aim of this study was to elucidate the role of FN1 in development of renal cell cancer (RCC) and to determine a prognostic relevance for optimal clinical management.
212 renal tissue samples (109 RCC, 86 corresponding tissues from adjacent normal renal tissue and 17 oncocytomas) were collected from patients undergoing surgery for renal tumors and subjected to total RNA extraction. Detection of FN1 mRNA expression was performed using quantitative real time PCR, three endogenous controls, renal proximal tubular epithelial cells (RPTEC) as biological control and the ΔΔCt method for calculation of relative quantities.
Mean tissue specific FN1 mRNA expression was found to be increased approximately seven fold comparing RCC and corresponding kidney control tissues (p < 0.001; ANOVA). Furthermore, tissue specific mean FN1 expression was increased approx. 11 fold in clear cell compared to papillary RCC (p = 9×10-5; Wilcoxon rank sum test). Patients with advanced disease had higher FN1 expression when compared to organ-confined disease (p < 0.001; Wilcoxon rank sum test). Applying subgroup analysis we found a significantly higher FN1 mRNA expression between organ-confined and advanced disease in the papillary and not in the clear cell RCC group (p = 0.02 vs. p = 0.2; Wilcoxon rank sum test). There was an increased expression in RCC compared to oncocytoma (p = 0.016; ANOVA).
To our knowledge, this is the first study to show that FN1 mRNA expression is higher in RCC compared to normal renal tissue. FN1 mRNA expression might serve as a marker for RCC aggressiveness, indicating early systemic progression particularly for patients with papillary RCC.
- Renal Cell Carcinoma
- Normal Renal Tissue
- Papillary RCCs
- Renal Proximal Tubular Epithelial Cell
- Papillary Renal Cell Carcinoma
Renal cell carcinoma (RCC) is a common urologic tumor and accounts for about 3% of all human malignancies . The annual mortality-to-incidence ratio of RCC is significantly higher compared to other urological malignancies, and its incidence has been increasing steadily in recent decades . Interestingly, even organ-confined RCC of comparable stage and grade can demonstrate a significantly-varying tendency towards tumor progression and systemic spread. Correspondingly, the development of metastases can be observed in a substantial number of patients with tumors initially classified as stage T1b or T2 even more than five years after the initial treatment, hereby demonstrating the limited value of classical patients' and tumor characteristics such as tumor stage and grade to predict the clinical outcome of an individual patient.
An essential step in local disease progression and in the formation of metastases is the invasion of tumour cells into the extracellular matrix. Cell adhesion molecules and extra-cellular matrix proteins support either an increase or a decrease in the ability of tumours cells to adhere to surrounding tissue. Among the extracellular matrix proteins identified, Fibronectin (FN) seems to play an important role in both inhibition and promotion of cellular attachment by interacting with different receptors.
FN is a glycoprotein that is involved in cellular adhesion and migration processes including embryogenesis, wound healing, blood coagulation, host defense, and metastasis. The molecule is widely distributed in healthy membrane, in the lamina propria, in vessel structures, nerves and smooth-muscle cell layers . However, up to now the function of FN is not clearly known [4, 5]. Few studies described the potential role of FN in different malignancies [5–8]. For example in hepatocellular carcinoma an overexpression of FN protein was found . Elevated plasma levels were detected in patients suffering from gastrointestinal and head/neck cancer . In non-malignant diseases particularly in thrombosis, hemostasis, vascular disease and platelet function the definitive role of FN is still unclear [9–11].
The aim of this study is to elucidate a possible role of FN1 in the development of RCC using mRNA expression analyses. 212 renal tissue samples from patients undergoing surgery for renal tumors were analysed using quantitative real time PCR. FN1 mRNA expression was significantly increased in RCC compared to corresponding normal renal tissue. Furthermore, our data suggest FN1 as marker for progressive disease especially in papillary RCC.
Clinical and histopathological data of patients with renal cell cancer
Number of patients
Age (mean; ± SD)
63 ± 11.9
LN metastasis 1
Advanced/metastatic disease (pT3-4 and/or N/M+)
Renal proximal tubular epithelial cells (RPTEC) were obtained from Lonza (Basel, Switzerland) and cultured according to the manufactures recommendations.
Quantitative real-time PCR analysis
Total RNA was isolated from 20 cyro sections (each 20 μm) using TriReagent (Ambion) according to the manufacturers' instructions. Furthermore, of each tissue sample two sections were stained with hematoxylin-eosin and evaluated by a pathologist (J.U.B). Total RNA was reverse-transcribed into single-strand complementary DNA (cDNA) using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). Quantitative real time PCR analyses were performed in duplicate with an ABI 7900 Fast Sequence Detection System using TaqMan gene expression assays and universal PCR master mix according to the manufacturer's specifications (Applied Biosystems). The TaqMan assays were FN1 (Assay ID: Hs00365058_m1), GUSB (Hs00939627_m1), RPL13A (Hs03043885_g1) and HPRT1 (Hs99999909_m1). The human GUSB, RPL13A and HPRT1 transcripts served as endogenous controls; cDNA derived from RPTEC primary cell transcripts served as biological control. Additional no-template, no reverse transcription and blank controls were included in each run.
Data were evaluated using the SDS 2.3 Manager, dataAssist V1.0 software and the ΔΔCt method [15, 16]. The three endogenous controls were combined using the dataAssist software V1.0 and "arithmetic mean" as normalization method. The method of Livak et al  and reference ΔCt values obtained from the biological control RPTEC were applied for calculation of ΔΔCt and relative quantity values, respectively. All statistics were done using the R-package 2.10.0 and Java Gui for R 1.7-0. For visual comparison of univariate data we used bean plots as a combination of one-dimensional scatter plots and density plots were generated using the bean plot package for R statistical software . In all tests, p < 0.05 was considered to indicate significance.
FN1mRNA expression in normal renal tissues, RCC and oncocytomas
FN1 mRNA expression in normal renal tissue, RCC and oncocytoma
Number of tissues
We investigated if any correlations of interest could be seen between the expression of FN1 and clinical parameters (table 1). The mean age of the cohort was 63 years (SD ± 11.9). Seventy patients were men (64.2%) and 39 patients were women (35.8%). Seventy-eight patients presented with clear cell RCC, 22 patients with papillary RCCs, and two patients with chromophobe RCC and seven patients with unclassified histology.
FN1 mRNA expression and its relationship to clinicopathological parameters in RCC has not yet been investigated. Functional studies have shown that FN and its receptors are important in mediating cell adhesion, migration, signal transduction and possibly in prevention of apoptosis . It is a component of the extracellular matrix, and cells adhere to FN via the integrin transmembrane receptors. Either up-regulation or down-regulation [19–21] of FN has been reported in several human cancers. The ability to promote epithelial cell migration and suppression of apoptosis, suggest that FN overexpression promote various tumors types [22, 23].
In the present study, a significantly increased expression of FN1 mRNA in RCC compared to normal renal tissue and oncocytoma has been shown. Both organ-confined (pT ≤ 2 and N0/M0) and advanced disease (pT≥3 and/or N+/M+) showed significant higher levels of FN1 mRNA expression compared to normal renal tissue. Moreover, patients with advanced disease had higher FN1 expression when compared to organ-confined disease. This supports the hypothesis that FN contributes to renal carcinogenesis and/or RCC progression.
There have been previous functional studies suggesting FN as a candidate marker for aggressive RCC. The first studies focusing on different RCC cell lines showed altered FN secretion and the possibility to influence mobility and invasiveness of these malignant cells [24–26].
A further interesting finding in our study was a significant increase in FN1 mRNA expression in clear cell RCC compared to papillary RCC. Our results generally suggest that an increased FN1 expression is correlated to a more progressive disease in RCC. Moreover, higher FN1 expression in clear cell RCC as compared to papillary RCC support the common belief that papillary tumors are less aggressive . On the other hand current data indicates that once papillary RCC has spread, it is associated with a poor survival and a higher risk of resistance to systemic therapy compared to clear cell RCC . This statement is supported by the fact that we found a significant higher FN1 mRNA expression between organ-confined and advanced disease in papillary RCC but not for clear cell RCC. Papillary RCC can be sub classified into types 1 and 2 as well as into less and more aggressive tumors. FN1 might be used to differentiate between papillary RCC with less or more aggressive potential.
To our knowledge, this is the first study to show that FN1 mRNA expression is significantly higher in RCC compared to normal renal tissue and oncocytoma. FN1 mRNA expression might serve as a marker for RCC aggressiveness, indicating early systemic progression particularly for patients with papillary RCC. Therefore, our data on FN1 encourages further investigations to enlighten the future role of FN1 in RCC.
- Schrader AJ, Rustemeier J, Rustemeier JC, Timmesfeld N, Varga Z, Hegele A, Olbert PJ, Hofmann R: Overweight is associated with improved cancer-specific survival in patients with organ-confined renal cell carcinoma. J Cancer Res Clin Oncol. 2009, 135: 1693-1699. 10.1007/s00432-009-0616-2.View ArticlePubMedGoogle Scholar
- Schrader AJ, Sevinc S, Olbert PJ, Hegele A, Varga Z, Hofmann R: [Gender-specific characteristics and survival of renal cell carcinoma]. Urologe A. 2008, 47 (1182): 1184-1186.Google Scholar
- Wilson CB, Leopard J, Cheresh DA, Nakamura RM: Extracellular matrix and integrin composition of the normal bladder wall. World J Urol. 1996, 14 (Suppl 1): S30-37.PubMedGoogle Scholar
- Akiyama SK, Olden K, Yamada KM: Fibronectin and integrins in invasion and metastasis. Cancer Metastasis Rev. 1995, 14: 173-189. 10.1007/BF00690290.View ArticlePubMedGoogle Scholar
- Warawdekar UM, Zingde SM, Iyer KS, Jagannath P, Mehta AR, Mehta NG: Elevated levels and fragmented nature of cellular fibronectin in the plasma of gastrointestinal and head and neck cancer patients. Clin Chim Acta. 2006, 372: 83-93. 10.1016/j.cca.2006.03.023.View ArticlePubMedGoogle Scholar
- Haglund C, Ylatupa S, Mertaniemi P, Partanen P: Cellular fibronectin concentration in the plasma of patients with malignant and benign diseases: a comparison with CA 19-9 and CEA. Br J Cancer. 1997, 76: 777-783.View ArticlePubMedPubMed CentralGoogle Scholar
- Torbenson M, Wang J, Choti M, Ashfaq R, Maitra A, Wilentz RE, Boitnott J: Hepatocellular carcinomas show abnormal expression of fibronectin protein. Mod Pathol. 2002, 15: 826-830. 10.1097/01.MP.0000024257.83046.7C.View ArticlePubMedGoogle Scholar
- Ylatupa S, Haglund C, Mertaniemi P, Vahtera E, Partanen P: Cellular fibronectin in serum and plasma: a potential new tumour marker?. Br J Cancer. 1995, 71: 578-582.View ArticlePubMedPubMed CentralGoogle Scholar
- Cho J, Mosher DF: Role of fibronectin assembly in platelet thrombus formation. J Thromb Haemost. 2006, 4: 1461-1469. 10.1111/j.1538-7836.2006.01943.x.View ArticlePubMedGoogle Scholar
- Mosher DF: Plasma fibronectin concentration: a risk factor for arterial thrombosis?. Arterioscler Thromb Vasc Biol. 2006, 26: 1193-1195. 10.1161/01.ATV.0000223342.15969.7a.View ArticlePubMedGoogle Scholar
- Orem C, Celik S, Orem A, Calapoglu M, Erdol C: Increased plasma fibronectin levels in patients with acute myocardial infarction complicated with left ventricular thrombus. Thromb Res. 2002, 105: 37-41. 10.1016/S0049-3848(01)00414-5.View ArticlePubMedGoogle Scholar
- Guinan P, Sobin LH, Algaba F, Badellino F, Kameyama S, MacLennan G, Novick A: TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997, 80 (5): 992-993. 10.1002/(SICI)1097-0142(19970901)80:5<992::AID-CNCR26>3.0.CO;2-Q.View ArticlePubMedGoogle Scholar
- Fuhrman SA, Lasky LC, Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. The American journal of surgical pathology. 1982, 6 (7): 655-663. 10.1097/00000478-198210000-00007.View ArticlePubMedGoogle Scholar
- Stenzl A, deKernion JB: Pathology, biology, and clinical staging of renal cell carcinoma. Seminars in oncology. 1989, 16 (1 Suppl 1): 3-11.PubMedGoogle Scholar
- Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008, 3: 1101-1108. 10.1038/nprot.2008.73.View ArticlePubMedGoogle Scholar
- Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.View ArticlePubMedGoogle Scholar
- Kampstra P: Beanplot: A Boxplot Alternative for Visual Comparison of Distributions. 2008, [http://www.cs.vu.nl/~pkampst/]Google Scholar
- de la Fuente MT, Casanova B, Garcia-Gila M, Silva A, Garcia-Pardo A: Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia. 1999, 13: 266-274. 10.1038/sj.leu.2401275.View ArticlePubMedGoogle Scholar
- Wolf M, El-Rifai W, Tarkkanen M, Kononen J, Serra M, Eriksen EF, Elomaa I, Kallioniemi A, Kallioniemi OP, Knuutila S: Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. Cancer Genet Cytogenet. 2000, 123: 128-132. 10.1016/S0165-4608(00)00319-8.View ArticlePubMedGoogle Scholar
- Sallinen SL, Sallinen PK, Haapasalo HK, Helin HJ, Helen PT, Schraml P, Kallioniemi OP, Kononen J: Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res. 2000, 60: 6617-6622.PubMedGoogle Scholar
- Chen M, Marinkovich MP, Jones JC, O'Toole EA, Li YY, Woodley DT: NC1 domain of type VII collagen binds to the beta3 chain of laminin 5 via a unique subdomain within the fibronectin-like repeats. J Invest Dermatol. 1999, 112: 177-183. 10.1046/j.1523-1747.1999.00491.x.View ArticlePubMedGoogle Scholar
- Takayasu H, Horie H, Hiyama E, Matsunaga T, Hayashi Y, Watanabe Y, Suita S, Kaneko M, Sasaki F, Hashizume K, et al: Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma. Clin Cancer Res. 2001, 7: 901-908.PubMedGoogle Scholar
- Tapper J, Kettunen E, El-Rifai W, Seppala M, Andersson LC, Knuutila S: Changes in gene expression during progression of ovarian carcinoma. Cancer Genet Cytogenet. 2001, 128: 1-6. 10.1016/S0165-4608(01)00386-7.View ArticlePubMedGoogle Scholar
- Schrader AJ, Rauer-Bruening S, Olbert PJ, Hegele A, Rustemeier J, Timmesfeld N, Varga Z, Hofmann R: Incidence and long-term prognosis of papillary renal cell carcinoma. J Cancer Res Clin Oncol. 2009, 135: 799-805. 10.1007/s00432-008-0515-y.View ArticlePubMedGoogle Scholar
- Brenner W, Gross S, Steinbach F, Horn S, Hohenfellner R, Thuroff JW: Differential inhibition of renal cancer cell invasion mediated by fibronectin, collagen IV and laminin. Cancer Lett. 2000, 155: 199-205. 10.1016/S0304-3835(00)00429-8.View ArticlePubMedGoogle Scholar
- Lohi J, Tani T, Leivo I, Linnala A, Kangas L, Burgeson RE, Lehto VP, Virtanen I: Expression of laminin in renal-cell carcinomas, renal-cell carcinoma cell lines and xenografts in nude mice. Int J Cancer. 1996, 68: 364-371. 10.1002/(SICI)1097-0215(19961104)68:3<364::AID-IJC15>3.0.CO;2-8.View ArticlePubMedGoogle Scholar
- Murata J, Saiki I, Yoneda J, Azuma I: Differences in chemotaxis to fibronectin in weakly and highly metastatic tumor cells. Jpn J Cancer Res. 1992, 83: 1327-1333.View ArticlePubMedGoogle Scholar
- Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, et al: Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005, 23: 2763-2771. 10.1200/JCO.2005.07.055.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/503/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.